The pharmacology of CP-154,526, a non-peptide antagonist of the CRH1 receptor: a review.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  CNS drug reviews

• Publication date

  2003-03-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1111/J.1527-3458.2003.TB00244.XPMID 12595912PMCID PMC6741649
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Suppression of conditioned fear by administration of CRF receptor antagonist CP-154,526

  2005cited by this paper
• Alpha-helical CRF blocks differential influence of corticotropin releasing factor (CRF) on appetitive and aversive memory retrieval in rats

  2005cited by this paper
• CRF antagonist reverses the “anxiogenic” response to ethanol withdrawal in the rat

  2005influential reference
• Conditioned responses to cocaine-related stimuli in cocaine abuse patients

  2005cited by this paper
• The validity of animal models of depression

  2004cited by this paper
• A simple and reliable conflict procedure for testing anti-anxiety agents

  2004cited by this paper
• Corticotropin-releasing factor potentiates acoustic startle in rats: Blockade by chlordiazepoxide

  2004cited by this paper
• Chlordiazepoxide attenuates response suppression induced by corticotropin-releasing factor in the conflict test

  2004cited by this paper
• 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related

  2002influential reference
• Effects of a Non-peptide CRF Antagonist (DMP696) on the Behavioral and Endocrine Sequelae of Maternal Separation

  2002cited by this paper
• Peripheral corticotropin-releasing factor induces diarrhea in rats: role of CRF1 receptor in fecal watery excretion.

  2002cited by this paper
• Urocortin, But Not Urocortin II, Protects Cultured Hippocampal Neurons from Oxidative and Excitotoxic Cell Death via Corticotropin-Releasing Hormone Receptor Type I

  2002cited by this paper
• Brain Penetrance, Receptor Occupancy and Antistress In Vivo Efficacy of a Small Molecule Corticotropin Releasing Factor Type I Receptor Selective Antagonist

  2002cited by this paper
• Differential actions of peripheral corticotropin-releasing factor (CRF), urocortin II, and urocortin III on gastric emptying and colonic transit in mice: role of CRF receptor subtypes 1 and 2.

  2002cited by this paper
• 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor(1) receptor antagonist. I. Biochemical and pharmacological characterization.

  2002cited by this paper
• The CRF peptide family and their receptors: yet more partners discovered.

  2002cited by this paper
• Human urocortin II, a new CRF-related peptide, displays selective CRF(2)-mediated action on gastric transit in rats.

  2002cited by this paper
• Up-regulation of nitric oxide synthase and modulation of the guanylate cyclase activity by corticotropin-releasing hormone but not urocortin II or urocortin III in cultured human pregnant myometrial cells

  2002cited by this paper
• Corticotropin-releasing Hormone Induces Fas Ligand Production and Apoptosis in PC12 Cells via Activation of p38 Mitogen-activated Protein Kinase*

  2002cited by this paper
• Brain pharmacokinetics of a nonpeptidic corticotropin-releasing factor receptor antagonist.

  2002cited by this paper
• Performance-enhancing effects of CRF-BP ligand inhibitors

  2001cited by this paper
• Long-term, progressive hippocampal cell loss and dysfunction induced by early-life administration of corticotropin-releasing hormone reproduce the effects of early-life stress

  2001cited by this paper
• Anxiolytic Properties of the Selective, Non-peptidergic CRF1 Antagonists, CP154,526 and DMP695: A Comparison to Other Classes of Anxiolytic Agent

  2001influential reference
• Corticotropin-releasing factor receptor type 1 mediates stress-induced relapse to cocaine-conditioned place preference in rats.

  2001cited by this paper
• Role of brain arachidonic acid cascade on central CRF1 receptor-mediated activation of sympatho-adrenomedullary outflow in rats.

  2001cited by this paper
• Divergent effects of corticotropin releasing hormone on endothelial cell nitric oxide synthase are associated with different expression of CRH type 1 and 2 receptors

  2001cited by this paper
• Corticotropin-releasing hormone promotes blastocyst implantation and early maternal tolerance

  2001cited by this paper
• Involvement of corticotropin-releasing factor subtype 1 receptor in the acquisition phase of learned helplessness in rats.

  2001influential reference
• Neuroprotective Effects of the CRF1 Antagonist R121920 after Permanent Focal Ischemia in the Rat

  2001cited by this paper
• Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor

  2001cited by this paper
• Corticotropin-releasing hormone in depression and post-traumatic stress disorder.

  2001cited by this paper
• Peripheral urocortin inhibits gastric emptying and food intake in mice: differential role of CRF receptor 2.

  2001cited by this paper
• Effects of CP-154,526 on responding during extinction from cocaine self-administration in rats.

  2001cited by this paper
• Expression of Corticotropin-Releasing Hormone Type 1 Receptor in Paraventricular Nucleus after Acute Stress

  2001cited by this paper
• Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor

  2001cited by this paper
• Effects of SR48968, a selective non-peptide NK2 receptor antagonist on emotional processes in rodents

  2001cited by this paper
• Role of CRF receptor 1 in central CRF-induced stimulation of colonic propulsion in rats.

  2001cited by this paper
• Urocortin II: A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors

  2001cited by this paper
• Involvement of the hypothalamus-pituitary-adrenal axis in antidepressant activity of corticotropin-releasing factor subtype 1 receptor antagonists in the rat learned helplessness test.

  2001cited by this paper
• The effects of CRA 1000, a non-peptide antagonist of corticotropin-releasing factor receptor type 1, on adaptive behaviour in the rat.

  2001influential reference
• Attenuation of fear conditioning by antisense inhibition of brain corticotropin releasing factor-2 receptor.

  2001cited by this paper
• A corticotropin releasing hormone receptor antagonist does not delay parturition in rats

  2000cited by this paper
• Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates.

  2000cited by this paper
• Use of a dual firefly and Renilla luciferase reporter gene assay to simultaneously determine drug selectivity at human corticotrophin releasing hormone 1 and 2 receptors.

  2000cited by this paper
• Effects of the CRF(1) receptor antagonist, CP 154,526, in the separation-induced vocalization anxiolytic test in rat pups.

  2000influential reference
• Antalarmin blockade of corticotropin releasing hormone-induced hypertension in rats.

  2000cited by this paper
• Urocortin and corticotropin-releasing factor receptor expression in the human colonic mucosa.

  2000cited by this paper
• Corticotropin-releasing hormone receptors mediate consensus interferon-alpha YM643-induced depression-like behavior in mice.

  2000cited by this paper
• Differential roles of corticotropin‐releasing factor receptor subtypes 1 and 2 in opiate withdrawal and in relapse to opiate dependence

  2000cited by this paper
• Corticotropin-releasing hormone-mediated neuroprotection against oxidative stress is associated with the increased release of non-amyloidogenic ß-precursor protein and with the suppression of nuclear factor κB.

  2000cited by this paper
• Chronic administration of the selective corticotropin-releasing factor 1 receptor antagonist CP-154,526: behavioral, endocrine and neurochemical effects in the rat.

  2000cited by this paper
• Role of Corticotropin‐Releasing Factor Receptor‐1 in Opiate Withdrawal

  2000cited by this paper
• Effects of the CRH Receptor Antagonist CP-154,526 on Intravenous Cocaine Self-administration in Rats

  2000cited by this paper
• Effect of corticotropin releasing factor receptor 1 antagonist on extracellular norepinephrine, dopamine and serotonin in hippocampus and prefrontal cortex of rats in vivo.

  2000cited by this paper
• Peripheral administration of CRF and urocortin: effects on food intake and the HPA axis in the marsupial Sminthopsis crassicaudata.

  2000cited by this paper
• Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated.

  2000cited by this paper
• Role of corticotropin-releasing factor (CRF) receptors in the anorexic syndrome induced by CRF.

  2000cited by this paper
• The Role of the CRH Type 1 Receptor in Autonomic Responses to Corticotropin-Releasing Hormone in the Rat

  2000cited by this paper
• The role of afferents to the locus coeruleus in the handling stress-induced increase in the release of noradrenaline in the medial prefrontal cortex: a dual-probe microdialysis study in the rat brain.

  2000cited by this paper
• The role of corticotrophin-releasing factor in stress-induced relapse to alcohol-seeking behavior in rats

  2000cited by this paper
• Corticotropin-releasing hormone-mediated neuroprotection against oxidative stress is associated with the increased release of non-amyloidogenic amyloid beta precursor protein and with the suppression of nuclear factor-kappaB.

  2000cited by this paper
• Suppression of Conditioned Fear by Administration of CRF Receptor Antagonist CP-154,526

  2000cited by this paper
• The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1 ,5-a]-pyrimidine: a corticotropin-releasing factor (hCRF1) antagonist.

  2000cited by this paper
• Peripheral corticotropin-releasing factor and stress-stimulated colonic motor activity involve type 1 receptor in rats.

  2000cited by this paper
• Effects of a novel corticotropin-releasing-hormone receptor type I antagonist on human adrenal function

  2000cited by this paper
• Involvement of corticotropin-releasing factor in the retrieval process of fear-conditioned ultrasonic vocalization in rats.

  2000cited by this paper
• Corticotropin‐releasing factor receptor type 1 mediates stress‐induced relapse to opiate dependence in rats

  2000cited by this paper
• Corticotropin-Releasing Hormone1 Receptors Mediate Consensus Interferon-α YM643-Induced Depression-Like Behavior in Mice

  2000cited by this paper
• 4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.

  2000influential reference
• Effects of Corticotropin-Releasing Factor on Neuronal Activity in the Serotonergic Dorsal Raphe Nucleus

  2000cited by this paper
• Autoradiographic and in situ hybridization localization of corticotropin‐releasing factor 1 and 2 receptors in nonhuman primate brain

  1999cited by this paper
• In vitro pharmacological profile of nonpeptide CRF1 receptor antagonists, CRA1000 and CRA1001.

  1999cited by this paper
• Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders?

  1999cited by this paper
• Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001.

  1999influential reference
• Peripheral urocortin delays gastric emptying: role of CRF receptor 2.

  1999cited by this paper
• Chronic administration of the non-peptide CRH type 1 receptor antagonist antalarmin does not blunt hypothalamic-pituitary-adrenal axis responses to acute immobilization stress.

  1999cited by this paper
• The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety.

  1999cited by this paper
• Differential effects of two corticotropin-releasing factor antagonists on conditioned defeat in male Syrian hamsters (Mesocricetus auratus).

  1999cited by this paper
• Stress-induced behaviors require the corticotropin-releasing hormone (CRH) receptor, but not CRH.

  1999cited by this paper
• Peripheral urocortin delays gastric emptying: role of CRF receptor 2.

  1999cited by this paper
• Functional, endogenously expressed corticotropin‐releasing factor receptor type 1 (CRF1) and CRF1 receptor mRNA expression in human neuroblastoma SH‐SY5Y cells

  1999cited by this paper
• Characterisation using microphysiometry of CRF receptor pharmacology.

  1999cited by this paper
• Stress, Corticotropin‐Releasing Hormone, Glucocorticoids, and the Immune/Inflammatory Response: Acute and Chronic Effects a

  1999cited by this paper
• Reduced anxiety-like and cognitive performance in mice lacking the corticotropin-releasing factor receptor 1.

  1999cited by this paper
• Potent mast cell degranulation and vascular permeability triggered by urocortin through activation of corticotropin-releasing hormone receptors.

  1999cited by this paper
• Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications.

  1999cited by this paper
• The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress.

  1999cited by this paper
• Molecular identification and analysis of a novel human corticotropin-releasing factor (CRF) receptor: the CRF2gamma receptor.

  1998cited by this paper
• Pharmacological characterisation of the recombinant human CRF binding protein using a simple assay.

  1998cited by this paper
• Central CRF inhibits gastric emptying of a nutrient solid meal in rats: the role of CRF2receptors.

  1998cited by this paper
• A corticotropin-releasing hormone type I receptor antagonist delays parturition in sheep.

  1998cited by this paper
• Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): development of CRFR2beta-selective antisauvagine-30.

  1998influential reference
• Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1

  1998cited by this paper
• CP-154,526, a selective, non-peptide antagonist of the corticotropin-releasing factor1 receptor attenuates stress-induced relapse to drug seeking in cocaine- and heroin-trained rats

  1998cited by this paper
• In vitro excitatory actions of corticotropin-releasing factor on rat colonic motility.

  1998cited by this paper
• Evidence for the involvement of corticotrophin‐releasing hormone in the pathogenesis of traumatic brain injury

  1998cited by this paper
• Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome

  1998cited by this paper
• Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents Comparison with diazepam and buspirone

  1998influential reference
• The Role of Corticotropin-Releasing Factor and Corticosterone in Stress- and Cocaine-Induced Relapse to Cocaine Seeking in Rats

  1998cited by this paper
• Central CRF inhibits gastric emptying of a nutrient solid meal in rats: the role of CRF2 receptors.

  1998cited by this paper

• Discovery and Characterization of Novel Spirotriazoloquinazolines as Potential Neuroprotectors: Synthesis, Computational Screening, and Preliminary In Vivo Evaluation

  2026cites this paper
• Restraint stress exacerbates indomethacin-induced gastric antral ulcers by gastroparesis via activation of corticotropin-releasing factor 2 receptors in refed mice.

  2024cites this paper
• In vitro and in vivo study of butyrylfentanyl and 4‐fluorobutyrylfentanyl in female and male mice: Role of the CRF1 receptor in cardiorespiratory impairment

  2024cites this paper
• Cortisol as a Target for Treating Mental Disorders: A Promising Avenue for Therapy.

  2023cites this paper
• Preterm Birth and Corticotrophin-Releasing Hormone as a Placental Clock.

  2022cites this paper
• A multiscale approach for bridging the gap between potency, efficacy, and safety of small molecules directed at membrane proteins

  2021cites this paper
• Exercise-Induced Adrenocorticotropic Hormone Response Is Cooperatively Regulated by Hypothalamic Arginine Vasopressin and Corticotrophin-Releasing Hormone

  2021cites this paper
• From atoms to cells: bridging the gap between potency, efficacy, and safety of small molecules directed at a membrane protein

  2021cites this paper
• An anti-CRF antibody suppresses the HPA axis and reverses stress-induced phenotypes

  2019cites this paper
• Corticotropin releasing factor-binding protein (CRF-BP) as a potential new therapeutic target in Alzheimer’s disease and stress disorders

  2019cites this paper
• Antagonizing the corticotropin releasing hormone receptor 1 with antalarmin reduces the progression of endometriosis

  2018cites this paper
• Brain and Gut CRF Signaling: Biological Actions and Role in the Gastrointestinal Tract.

  2018cites this paper
• The non-peptide CRH1-antagonist CP-154,526 elicits a paradoxical route-dependent activation of the HPA axis.

  2017cites this paper
• Structure and Function of Small Non-Peptide CRF Antagonists and their Potential Clinical Use.

  2017cites this paper
• Neuroanatomical pathways underlying the effects of hypothalamo-hypophysial-adrenal hormones on exploratory activity

  2017cites this paper
• The effects of enhancing endocannabinoid signaling and blocking corticotrophin releasing factor receptor in the amygdala and hippocampus on the consolidation of a stressful event.

  2017cites this paper
• Control of Stress-Induced ACTH Secretion by Vasopressin and CRH: Additional Evidence

  2016cites this paper
• Die neuronale Mediation von Stress am Beispiel tierexperimenteller Modelle

  2015cites this paper
• Structural Analogy — Direct Similarity Versus Topographical Complementarity

  2015cites this paper
• Drug-induced suppression of ACTH secretion does not promote anti-depressive or anxiolytic effects.

  2014cites this paper
• Orexin 1 receptor antagonists in compulsive behavior and anxiety: possible therapeutic use

  2014cites this paper
• Pharmacogenetics of Antidepressant Drugs: An Update

  2014cites this paper
• Preclinical metabolism and pharmacokinetics of NVS-CRF38, a potent and orally bioavailable corticotropin-releasing factor receptor 1 antagonist

  2014cites this paper
• Controversies about a common etiology for eating and mood disorders

  2014cites this paper
• Pharmacogenetics of Antidepressant Drugs

  2014cites this paper
• A possible solution for hair loss by inhibiting corticotropin-releasing factor (CRF) receptor from traditional Chinese medicine

  2014cites this paper
• Prevention of Alcohol-Heightened Aggression by CRF-R1 Antagonists in Mice: Critical Role for DRN-PFC Serotonin Pathway

  2014cites this paper
• Differential Effect of Orexin-1 and CRF-1 Antagonism on Stress Circuits: a fMRI Study in the Rat with the Pharmacological Stressor Yohimbine

  2013cites this paper
• Pharmacogenetics of antidepressant drugs: An update after almost 20 years of research

  2013cites this paper
• Non-peptide ligands in the characterization of peptide receptors at the interface between neuroendocrine and mental diseases

  2013cites this paper
• The Newly Developed CRF1-Receptor Antagonists, NGD 98-2 and NGD 9002, Suppress Acute Stress-Induced Stimulation of Colonic Motor Function and Visceral Hypersensitivity in Rats

  2013cites this paper
• Pharmacogenetics of antidepressive drugs: a way towards personalized treatment of major depressive disorder.

  2012cites this paper
• Pharmacogenetics of antidepressants and mood stabilizers.

  2012cites this paper
• Pharmacogenetics in Psychiatry

  2012cites this paper
• Quantification of extracellular levels of corticosterone in the basolateral amygdaloid complex of freely-moving rats: a dialysis study of circadian variation and stress-induced modulation.

  2012cites this paper
• The effects of the urocortins and the endomorphins on the mediators of the stress response

  2011cites this paper
• Pharmacogenetics of antidepressant response.

  2011cites this paper
• Restraint stress-induced reduction in prepulse inhibition in Brown Norway rats: role of the CRF2 receptor.

  2011influential citation
• Estradiol effects on behavior and serum oxytocin are modified by social status and polymorphisms in the serotonin transporter gene in female rhesus monkeys.

  2011cites this paper
• The Hippocampus, Neurotrophic Factors and Depression

  2011cites this paper
• Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder

  2010cites this paper
• Functional hypothalamic amenorrhea due to increased CRH tone in melanocortin receptor 2-deficient mice.

  2010cites this paper
• Pharmacogenomics of Depression

  2010cites this paper
• Pharmacogenetics of Antidepressants

  2010cites this paper
• REVIEW: Ethanol consumption: how should we measure it? Achieving consilience between human and animal phenotypes

  2010cites this paper
• Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stress-related disorders: evidence from animal models.

  2010cites this paper
• Endocrine and Metabolic Agents

  2010cites this paper
• Hippocampal changes associated with early-life adversity and vulnerability to depression.

  2010cites this paper
• Novel Therapeutic Strategies for Bipolar Disorder

  2010cites this paper
• Putative Drugs and Targets for Bipolar Disorder

  2009cites this paper
• Neuroendocrine control of the gut during stress: corticotropin-releasing factor signaling pathways in the spotlight.

  2009cites this paper
• CONTRIBUTION OF HPA ACTIVITY AND ENVIRONMENTAL STRESS TO VULNERABILITY FOR SMOKING IN ADOLESCENTS

  2009cites this paper
• Social Subordination and Polymorphisms in the Gene Encoding the Serotonin Transporter Enhance Estradiol Inhibition of Luteinizing Hormone Secretion in Female Rhesus Monkeys1

  2009cites this paper
• Cortagine, a CRF1 agonist, induces stresslike alterations of colonic function and visceral hypersensitivity in rodents primarily through peripheral pathways.

  2009influential citation
• Meiner Familie

  2008cites this paper
• Effects of antalarmin, a CRF receptor 1 antagonist, on fright reaction and endocrine stress response in crucian carp (Carassius carassius)

  2008cites this paper
• Corticotropin-releasing factor type 1 receptors mediate the visceral hyperalgesia induced by repeated psychological stress in rats.

  2008cites this paper
• Neurobiological and psychosocial processes associated with depressive and substance-related disorders in adolescents.

  2008cites this paper
• Medication Development for the Treatment of Substance Abuse

  2008cites this paper
• From Hans Selye's Discovery of Biological Stress to the Identification of Corticotropin‐ Releasing Factor Signaling Pathways

  2008cites this paper
• Bipolar disorder: candidate drug targets.

  2008cites this paper
• Modulation de la neurogenèse en utilisant du modafinil

  2008cites this paper
• Role of brain nicotinic acetylcholine receptor in centrally administered corticotropin-releasing factor-induced elevation of plasma corticosterone in rats.

  2008cites this paper
• Drug challenges reveal differences in mediation of stress facilitation of voluntary alcohol drinking and withdrawal-induced anxiety in alcohol-preferring P rats.

  2007cites this paper
• Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression.

  2007cites this paper
• Suppression of Adrenocorticotrophic Hormone Secretion by Simultaneous Antagonism of Vasopressin 1b and CRH-1 Receptors on Three Different Stress Models

  2007cites this paper
• Corticotropin-releasing factor receptors and stress-related alterations of gut motor function.

  2007cites this paper
• Nonpeptidic ligands for peptide-activated G protein-coupled receptors.

  2007cites this paper
• Novel Pharmacologic Treatment of Stress and Addiction

  2007cites this paper
• Effects of the CRF1 antagonist antalarmin on cocaine self-administration and discrimination in rhesus monkeys.

  2006cites this paper
• The corticotropin-releasing factor (CRF)(1) receptor antagonists CP154,526 and DMP695 inhibit light-induced phase advances of hamster circadian activity rhythms.

  2006cites this paper
• Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder.

  2006cites this paper
• Recent advances in small molecule antagonists of the corticotropin-releasing factor type-1 receptor-focus on pharmacology and pharmacokinetics.

  2006cites this paper
• Links between depression and substance abuse in adolescents: neurobiological mechanisms.

  2006cites this paper
• Anxiogenic and aversive effects of corticotropin-releasing factor (CRF) in the bed nucleus of the stria terminalis in the rat: role of CRF receptor subtypes

  2006influential citation
• Anxiogenic-like effect of chronic corticosterone in the light-dark emergence task in mice.

  2006cites this paper
• Antidepressant-Like Effects of the Corticotropin-Releasing Factor 1 Receptor Antagonist, SSR125543, and the Vasopressin 1b Receptor Antagonist, SSR149415, in a DRL-72 s Schedule in the Rat

  2006cites this paper
• Corticotropin-releasing factor type-1 receptor antagonists: the next class of antidepressants?

  2006cites this paper
• CRF1 receptors as a therapeutic target for irritable bowel syndrome.

  2006cites this paper
• The pharmacology of DMP696 and DMP904, non-peptidergic CRF1 receptor antagonists.

  2006cites this paper
• Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application.

  2006cites this paper
• Corticotropin-releasing factor receptor antagonists

  2006cites this paper
• Corticotropin Releasing Factor Receptors and Agonistic Behavior in Syrian Hamsters

  2006cites this paper
• El futuro de la farmacoterapia antidepresiva

  2006cites this paper
• Links Between Depression and Substance Abuse in Adolescents Mechanisms

  2006cites this paper
• Effects of CP 154,526, a CRF1 receptor antagonist, on behavioral responses to cocaine in rats.

  2005cites this paper
• Can CRF1 receptor antagonists become antidepressant and/or anxiolytic agents?

  2005cites this paper
• The neurobiology of depression: inroads to treatment and new drug discovery.

  2005cites this paper
• Nonpeptide ligands that target peptide-activated GPCRs in inflammation.

  2005cites this paper
• Vielseitige direkte Synthese von oligosubstituierten Pyrrolen durch Cycloaddition von α‐metallierten Isocyaniden an Acetylene

  2005cites this paper
• Divergent role for CRF1 and CRF2 receptors in the modulation of visceral pain

  2005cites this paper
• NBI 30775 ( R 121919 ) , an Orally Active Antagonist of the Corticotropin-releasing Factor ( CRF ) Type-1 Receptor for the Treatment of Anxiety and Depression

  2005cites this paper
• Pharmacological modulation of repeated ethanol withdrawal-induced anxiety-like behavior differs in alcohol-preferring P and Sprague-Dawley rats.

  2005cites this paper
• The Flinders Sensitive Line rat: a selectively bred putative animal model of depression.

  2005cites this paper
• Corticotropin-releasing factor type II (CRF-sub-2) receptors in the bed nucleus of the stria terminalis modulate conditioned defeat in Syrian hamsters (Mesocricetus auratus).

  2005cites this paper
• Corticotropin-releasing factor type II (CRF₂) receptors in the bed nucleus of the stria terminalis modulate conditioned defeat in Syrian hamsters (Mesocricetus auratus).

  2005cites this paper
• Bases biochimiques et neurobiologiques de la psychiatrie

  2005cites this paper
• Mood stabilizers target cellular plasticity and resilience cascades

  2005cites this paper
• Versatile direct synthesis of oligosubstituted pyrroles by cycloaddition of alpha-metalated isocyanides to acetylenes.

  2005cites this paper
• Sensitivity to stress: dysregulation of CRF pathways and disease development.

  2005cites this paper